May 03, 2016 10:39 AM ET

Biotechnology

Company Overview of AnaptysBio, Inc.

Company Overview

AnaptysBio, Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. It is developing ANB020, a pro-inflammatory cytokine antibody that inhibits the activity of interleukin-33; and ANB019, an antibody that inhibits the function of the interleukin-36-receptor. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

10421 Pacific Center Court

Suite 200

San Diego, CA 92121

United States

Founded in 2005

47 Employees

Phone:

858-362-6295

Fax:

858-362-6296

Key Executives for AnaptysBio, Inc.

Chief Executive Officer, President and Director
Age: 39
Co-Founder
Age: 52
Chief Financial Officer
Age: 49
Head of Project Management
Chief Development Officer
Age: 58
Compensation as of Fiscal Year 2015.

AnaptysBio, Inc. Key Developments

AnaptysBio, Inc. Announces First-In-Human Dosing of Anti-IL-33 Antibody

AnaptysBio, Inc. announced first-in-human dosing of its proprietary anti-IL-33 antibody (ANB020) in a Phase I clinical trial. The double-blind, placebo-controlled single and multiple ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB020 in healthy volunteers. Interleukin-33, or IL-33, is a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 acts on white blood cell types that subsequently release atopic disease-mediating cytokines such as IL-5, IL-13 and IL-4. Since ANB020 potently inhibits IL-33 function, and acts upstream broadly across the key cell types involved in atopy, AnaptysBio believes its mechanism has potential advantages in human therapy over agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has been genetically validated through human studies published in the medical literature. Subsequent to the completion of this Phase I study, AnaptysBio plans to continue clinical development of ANB020 in patients with atopic dermatitis, peanut allergy and asthma.

AnaptysBio, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM

AnaptysBio, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director.

AnaptysBio, Inc. Announces Appointment of James A. Schoeneck to Board of Directors

AnaptysBio, Inc. announced the appointment of James A. Schoeneck to its Board of Directors. Mr. Schoeneck is currently President & CEO of Depomed.

Similar Private Companies By Industry

Company Name Region
Ceregene, Inc. United States
Xantech Pharmaceuticals Inc. United States
Synthorx Inc. United States
Gala Therapeutics United States
StemTroniX, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 13, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AnaptysBio, Inc., please visit www.anaptysbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.